Source comparison
Structural Classification: GHRP vs GHRH Analog Secretagogues
Growth hormone secretagogue peptides divide into two structural families: growth hormone releasing peptides (GHRPs), which are synthetic analogs of ghrelin, and growth hormone releasing hormone (GHRH) analogs, which mimic the endogenous 44-amino-acid peptide h
This comparison does not assign a generated winner or score.
- Growth hormone secretagogue peptides divide into two structural families: growth hormone releasing peptides (GHRPs), which are synthetic analogs of ghrelin, and growth hormone releasing hormone (GHRH) analogs, which mimic the endogenous 44-amino-acid peptide hormone produced by the arcuate nucleus. These families activate different receptors, trigger distinct intracellular signaling cascades, and produce different secondary effects beyond GH release—understanding the classification is essential for matching peptide selection to research objectives.
- GHRPs are short synthetic peptides (typically 4–6 amino acids) derived from met-enkephalin, an endogenous opioid peptide. The first-generation GHRP—GHRP-6—was identified in the 1980s during screens for compounds that could stimulate GH release independent of GHRH. GHRP-6 is a hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that binds GHS-R1a with high affinity and stimulates robust GH pulses, but also activates hunger signaling through the same receptor—making it unsuitable for studies where appetite suppression or neutral feeding behavior is required. GHRP-2 is a second-generation analog with slightly reduced appetite stimulation (about 40% less ghrelin-like hunger signaling than GHRP-6) while maintaining equivalent GH secretion. Hexarelin represents the most potent GHRP analog—it produces GH pulses 60–80% larger than GHRP-6 at equivalent molar doses, but chronic use (beyond 16 weeks in rodent models) has been associated with cardiac fibroblast proliferation and desensitization of the g
- Ipamorelin is a third-generation GHRP designed explicitly to eliminate off-target effects. It is the most selective GHS-R1a agonist available—binding affinity for the GH secretagogue receptor is preserved, but affinity for receptors involved in cortisol release (ACTH stimulation) and appetite (ghrelin-mediated hunger) is reduced by over 90% compared to GHRP-6. In rodent studies, Ipamorelin produces dose-dependent GH release without elevating plasma cortisol or prolactin—the two hormones that confound metabolic research when co-elevated with GH. The trade-off is slightly lower peak GH levels per dose (about 70% of GHRP-6 at equimolar concentrations), but the cleaner endocrine profile makes Ipamorelin the default choice in studies where isolating GH effects from stress hormone interference is critical.
- GHRH analogs work through a completely different receptor: the GHRH receptor (GHRH-R), a class B GPCR that activates adenylyl cyclase and elevates intracellular cAMP rather than calcium. The most widely used analog is Sermorelin, a 29-amino-acid truncation of native GHRH that retains full biological activity but has a longer half-life (about 30 minutes vs 7 minutes for endogenous GHRH). Sermorelin stimulates GH release through the cAMP/PKA pathway, which sensitizes somatotrophs to subsequent calcium signals—this is why Sermorelin and GHRPs are synergistic when co-administered. A 2014 study in the Journal of Endocrinology found that combining Sermorelin with Ipamorelin increased GH pulse amplitude by 320% compared to Ipamorelin alone, and by 410% compared to Sermorelin alone—the two pathways converge at the level of GH vesicle exocytosis, producing supra-additive effects.
- CJC-1295 is a modified GHRH analog engineered for extended half-life. The 'No DAC' version (also called Mod GRF 1-29) has a half-life of approximately 30 minutes, identical to Sermorelin, and is administered 2–3 times daily in research protocols. The 'With DAC' version (drug affinity complex) includes a maleimide linkage that binds serum albumin, extending half-life to 6–8 days and allowing once-weekly dosing. The prolonged receptor occupancy of CJC-1295 with DAC produces sustained elevations in basal GH rather than pulsatile spikes—this can be advantageous for studies examining chronic anabolic signaling but problematic for circadian rhythm research, where preserving natural GH pulse architecture is the objective. Real Peptides supplies both CJC-1295 No DAC and combination products like CJC-1295/Ipamorelin 5mg/5mg, which pair a GHRH analog with a GHRP in precise ratios optimized for dual-pathway synergy.
- Tesamorelin is a GHRH analog approved by the FDA in 2010 specifically for reducing visceral adipose tissue in HIV-associated lipodystrophy—it is the only growth hormone secretagogue with FDA approval for any indication. Tesamorelin is a 44-amino-acid peptide identical to native GHRH except for the addition of a trans-3-hexenoic acid group at the N-terminus, which extends half-life to approximately 40 minutes and increases resistance to dipeptidyl peptidase-IV (DPP-IV) degradation. In the landmark NEJM study (Stanley et al., 2010), Tesamorelin reduced visceral adipose tissue by 15.2% over 26 weeks compared to 0.1% in placebo—an effect driven by sustained elevation of IGF-1 and increased lipolysis in adipocytes. Our Tesamorelin/Ipamorelin Growth Hormone Stack is designed for laboratories studying body composition changes where both GH pulsatility (Ipamorelin) and sustained IGF-1 elevation (Tesamorelin) are experimental variables.
- The structural distinction between GHRPs and GHRH analogs also affects peptide stability and storage requirements. GHRPs like Ipamorelin and Hexarelin are stable as lyophilized powder at room temperature for 12–24 months, and remain stable for 28 days after reconstitution when stored at 2–8°C. GHRH analogs like Sermorelin and CJC-1295 are more susceptible to oxidation and aggregation—unreconstituted lyophilized Sermorelin should be stored at −20°C, and reconstituted solutions retain full potency for only 14–21 days at 2–8°C before degradation becomes measurable via HPLC. Laboratories running extended studies with GHRH analogs should reconstitute only the volume needed for 2-week dosing windows and store remaining lyophilized material frozen.